We are live on
!
Find out more
Federated Hermes Portfolio holdings
AUM
$69.6B
1-Year Est. Return
42.52%
This Fund
S&P 500
This Quarter
Est. Return
+1.34%
1 Year Est. Return
+42.52%
3 Year Est. Return
+132.48%
5 Year Est. Return
+152.58%
10 Year Est. Return
+652.43%
AUM
$42.2B
AUM Growth
-$1.23B
(-2.8%)
Cap. Flow
-$952M
Cap. Flow
% of AUM
-2.26%
Top 10 Holdings %
Top 10 Hldgs %
14.57%
Holding
2,171
New
150
Increased
772
Reduced
960
Closed
152
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$156M |
| 2 |
Prologis
PLD
|
+$150M |
| 3 |
Chevron
CVX
|
+$109M |
| 4 |
Qualcomm
QCOM
|
+$101M |
| 5 |
Paycom
PAYC
|
+$90.8M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
FUSN
Fusion Pharmaceuticals Inc. Common Shares
FUSN
|
+$230M |
| 2 |
Kimberly-Clark
KMB
|
+$160M |
| 3 |
Stanley Black & Decker
SWK
|
+$130M |
| 4 |
Paychex
PAYX
|
+$113M |
| 5 |
Dominion Energy
D
|
+$105M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 18.81% |
| 2 | Healthcare | 17.11% |
| 3 | Financials | 12.73% |
| 4 | Industrials | 9.87% |
| 5 | Consumer Discretionary | 9.74% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1801
Universal Electronics
UEIC
$65.5M
| $7.89K | ﹤0.01% |
679
-129
| -16% | -$1.45K |
|
1802
Aveanna Healthcare
AVAH
$3.12B
| $7.81K | ﹤0.01% |
2,831
+1
| +0% | +$2 |
|
1803
Journey Medical
DERM
$208M
| $7.5K | ﹤0.01% |
1,329
| – | – |
|
1804
Cal-Maine
CALM
$3.47B
| $7.39K | ﹤0.01% |
121
-647
| -84% | -$38.4K |
|
1805
Compass
COMP
$7.95B
| $7.36K | ﹤0.01% |
2,045
+2,044
| +204,400% | +$7.49K |
|
1806
Astrana Health
ASTH
$1.9B
| $7.3K | ﹤0.01% |
180
| – | – |
|
|
ASRT
1807
DELISTED
Assertio
ASRT
| $7.04K | ﹤0.01% |
378
+215
| +132% | +$3.19K |
|
1808
American Coastal Insurance
ACIC
$432M
| $6.89K | ﹤0.01% |
653
+588
| +905% | +$6.61K |
|
1809
Babcock & Wilcox
BW
$1.04B
| $6.82K | ﹤0.01% |
4,706
+934
| +25% | +$1.12K |
|
|
MRNS
1810
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
| $6.82K | ﹤0.01% |
+5,826
| New | +$14.6K |
|
1811
iShares MSCI Japan Value ETF
EWJV
$788M
| $6.78K | ﹤0.01% |
213
-73
| -26% | -$2.35K |
|
1812
Bioventus
BVS
$888M
| $6.78K | ﹤0.01% |
1,179
-660
| -36% | -$3.62K |
|
1813
1stdibs.com
DIBS
$151M
| $6.77K | ﹤0.01% |
1,507
+976
| +184% | +$5.33K |
|
1814
BARK
BARK
$79.9M
| $6.66K | ﹤0.01% |
184
+36
| +24% | +$923 |
|
1815
Orrstown Financial Services
ORRF
$838M
| $6.54K | ﹤0.01% |
239
+85
| +55% | +$2.21K |
|
1816
PLAYSTUDIOS Inc
MYPS
$59.1M
| $6.5K | ﹤0.01% |
+3,142
| New | +$7.39K |
|
1817
PMV Pharmaceuticals
PMVP
$72.7M
| $6.29K | ﹤0.01% |
3,883
+259
| +7% | +$467 |
|
|
WHWK
1818
Whitehawk Therapeutics
WHWK
$233M
| $6.27K | ﹤0.01% |
4,294
+580
| +16% | +$1.07K |
|
1819
Mohawk Industries
MHK
$8.74B
| $6.25K | ﹤0.01% |
55
-816
| -94% | -$94.9K |
|
|
LPSN
1820
DELISTED
LivePerson
LPSN
| $6.22K | ﹤0.01% |
714
+136
| +24% | +$1.31K |
|
|
USAP
1821
DELISTED
Universal Stainless & Alloy
USAP
| $5.86K | ﹤0.01% |
214
+82
| +62% | +$2.42K |
|
1822
a.k.a. Brands
AKA
$119M
| $5.81K | ﹤0.01% |
381
| – | – |
|
1823
Immuneering
IMRX
$287M
| $5.77K | ﹤0.01% |
+4,509
| New | +$7.41K |
|
1824
UBS Group
UBS
$158B
| $5.67K | ﹤0.01% |
192
+18
| +10% | +$535 |
|
1825
OneSpan
OSPN
$657M
| $5.67K | ﹤0.01% |
+442
| New | +$5.32K |
|
Similar funds
Federated Hermes's Q2 2024 Portfolio in Review
As of Q2 2024, Federated Hermes held 2,171 positions worth $42.2B, down 2.8% from $43.4B the previous quarter. Its ten largest holdings account for 15% of the portfolio.
Federated Hermes's Q2 2024 filing shows 150 new, 772 increased, 960 reduced and 152 closed positions. Its largest new stake was Loar Holdings: 729,296 shares worth $39M. The largest sale was Fusion Pharmaceuticals Inc. Common Shares, an estimated $230M.
By sector, the portfolio is most concentrated in Technology at 19% of assets, up from 17% a quarter earlier, followed by Healthcare and Financials.
- Federated Hermes's largest Q2 2024 buy was Loar Holdings: 729,296 shares worth $39M.
- Federated Hermes added most to Bristol-Myers Squibb in Q2 2024, an estimated $156M increase.
- Federated Hermes's biggest Q2 2024 reduction was Kimberly-Clark, cutting an estimated $160M.
- Federated Hermes fully exited Fusion Pharmaceuticals Inc. Common Shares in Q2 2024, selling an estimated $230M.
- Federated Hermes's ten largest holdings make up 15% of its $42.2B portfolio in Q2 2024.
- Federated Hermes opened 150 new positions and closed 152 in Q2 2024.
- Federated Hermes's portfolio value fell 2.8% quarter-over-quarter to $42.2B.
Based on Federated Hermes's 13F filing for Q2 2024, filed 8 Aug 2024.